CD276 and myeloid neoplasm: Next, we evaluated the specific binding of the murine CD276 hybridoma-derived antibody clone 8H8 [5] to assess the surface expression of CD276 on various leukemia cell lines representing a broad spectrum of myeloid malignancies, such as EOL-1, HL-60, Kasumi-1, KG-1a, MOLM-13, MV-4-11, NB-4, Nomo-1, SKM-1, THP-1 and U937.